BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026GlobeNewsWire • 10/28/26
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million LivesGlobeNewsWire • 10/26/26
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical GroupGlobeNewsWire • 10/19/26
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered LivesGlobeNewsWire • 10/13/26
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™GlobeNewsWire • 09/08/26
Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?Zacks Investment Research • 08/27/26
BrainsWay Reports Second Quarter 2026 Financial Results and Operational HighlightsGlobeNewsWire • 08/12/26
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 07/22/26
4 Medical Products Stocks Poised to Win Despite Industry HeadwindsZacks Investment Research • 07/20/26
BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive DisorderGlobeNewsWire • 06/29/26
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered LivesGlobeNewsWire • 06/22/26
BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual MeetingGlobeNewsWire • 06/09/26